Collegium Pharmaceutical, Inc.
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $-74.9M | $-94.2M | $-27.3M | $-17.9M | $-16.2M |
| Depreciation & Amortization | $594.0K | $655.0K | $171.0K | $187.0K | — |
| Depreciation | $336.0K | $258.0K | $171.0K | $187.0K | $169.0K |
| Amortization | $258.0K | $397.0K | — | — | — |
| Stock-Based Compensation | $7.9M | $5.8M | $2.2M | $22.0K | $62.0K |
| Net Cash from Operating Activities | $-67.0M | $-75.1M | $-21.6M | $-17.9M | $-16.5M |
| Investing Activities | |||||
| Capital Expenditures | $990.0K | $477.0K | $362.0K | $8.0K | $206.0K |
| Business Acquisitions | — | — | — | — | — |
| Net Cash from Investing Activities | $-990.0K | $-3.0M | $-362.0K | — | — |
| Financing Activities | |||||
| Dividends Paid | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — |
| Net Cash from Financing Activities | $33.5M | $135.6M | $116.0M | — | — |
| Net Change in Cash | $-34.5M | $57.5M | $94.1M | — | — |
| Free Cash Flow | $-68.0M | $-75.5M | $-21.9M | $-18.0M | $-16.7M |